VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Camilla Höglund  1     Mohamed Attauabi  2     Janne Fassov  3     Kenneth Bo Pedersen  4     Heidi Bansholm Hansen  5     Signe Wildt  6     Anders Neumann  7     Michael Dam Jensen  8     Cecilie Lind     Henrik Albæk Jacobsen     Ana-Maria Popa     Akbar Molazahi     Kent Haderslev     Claus Aalykke     jens kjeldsen     Natalia Pedersen     Wojciech Cebula     Jakob Benedict Seidelin     Torben    
1 OUH Svendborg Hospital,Svendborg,Denmark
2 Herlev Hospital,Herlev,Denmark
3 Aarhus University Hospital,Aarhus,Denmark
4 Hospital of South West Denmark,Esbjerg,Denmark
5 North Zealand University Hospital,Frederikssund,Denmark
6 Zealand University Hospital,Koege,Denmark
7 Regional Hospital Viborg,Viborg,Denmark
8 Lillebaelt Hospital,Vejle,De

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing